Sai-yang T. Zhang

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.

A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: July 20, 2026

PROTACs in 2025: from the laboratory concept to clinical breakthrough.

PROTACs in 2025: from the laboratory concept to clinical breakthrough.

Journal: Future medicinal chemistry

Published: April 06, 2026

Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency.

Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency.

Journal: Future medicinal chemistry

Published: April 04, 2026

Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia.

Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia.

Journal: Bioorganic chemistry

Published: October 23, 2025

Chalcones and their derivatives as inhibitors of key ABC transporters (ABCB1, ABCG2) to overcome tumor multidrug resistance.

Chalcones and their derivatives as inhibitors of key ABC transporters (ABCB1, ABCG2) to overcome tumor multidrug resistance.

Journal: Bioorganic chemistry

Published: August 12, 2025

Advances in light-controllable PROTACs: Design strategies, therapeutic applications and current challenges.

Advances in light-controllable PROTACs: Design strategies, therapeutic applications and current challenges.

Journal: Bioorganic chemistry

Published: July 24, 2025

Discovery of novel 1,2,3-triazole arylamide derivatives bearing dithiocarbamate moiety as dual inhibitors of tubulin and LSD1 with potent anticancer activity.

Discovery of novel 1,2,3-triazole arylamide derivatives bearing dithiocarbamate moiety as dual inhibitors of tubulin and LSD1 with potent anticancer activity.

Journal: European journal of medicinal chemistry

Published: May 13, 2025

Discovery of novel coumarin-sulfonates as tubulin polymerization inhibitors targeting the colchicine-binding site with potent anticancer activities.

Discovery of novel coumarin-sulfonates as tubulin polymerization inhibitors targeting the colchicine-binding site with potent anticancer activities.

Journal: Bioorganic & medicinal chemistry letters

Published: March 29, 2025

ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy.

ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy.

Journal: European journal of medicinal chemistry

Published: February 05, 2025

Current Progress of Hederagenin and Its Derivatives for Disease Therapy (2017-Present).

Current Progress of Hederagenin and Its Derivatives for Disease Therapy (2017-Present).

Journal: Molecules (Basel, Switzerland)

Published: January 21, 2025

Discovery of novel tranylcypromine-indazole-based derivatives as LSD1 inhibitors for acute myeloid leukemia treatment.

Discovery of novel tranylcypromine-indazole-based derivatives as LSD1 inhibitors for acute myeloid leukemia treatment.

Journal: European journal of medicinal chemistry

Published: January 10, 2025

Discovery of 2,4-diaminopyrimidine derivatives as potent inhibitors of FAK capable of activating the Hippo pathway for the treatment of esophageal squamous cell carcinoma.

Discovery of 2,4-diaminopyrimidine derivatives as potent inhibitors of FAK capable of activating the Hippo pathway for the treatment of esophageal squamous cell carcinoma.

Journal: European journal of medicinal chemistry

Published: December 20, 2024

Showing 1-12 of 75

Last Updated: 09/26/2026